Genenta Science has strengthened its partnership with AGC Biologics by amending their agreement to include an exclusive GMP suite at the CDMO’s Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s lead cell therapy candidate.
Genenta’s therapy, Temferon, is a lenti-virus immunotherapy based on hematopoietic stem progenitor cells, enabling controlled and targeted IFNa expresssion within the tumor microenvironment of solid tumors. According to Genenta, Temferon’s unique potential to reprogram the tumor microenvironment not only enhances the potential efficacy of Temferon as a monotherapy but also suggests promising synergies when combined with various immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies.
The company began a metastatic renal cell cancer phase 1/2a trial in Q4 2024 and expects to treat six patients by the end of the first half of 2025. Temferon is also being studied in glioblastoma multimforme, an aggressive brain tumor. Genenta projects that it will utilize the ACG suite to manufacture 27 autologous drug products in 2025.
AGC Biologics acquired the Milan site in July 2020, expanding it in 2023. The expansion added five suspension single-use bioreactors, a new automated filling line, full dedicated warehouse space and additional process development lab space.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!